Keyword Search
 
2017 | 2016
08/31/17

Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products

Provides Significant Non-Dilutive Funding to Execute R&D Strategy Sharpens Focus on Proprietary ADAPTIR™ Protein Therapeutic Platform Retains IXINITY® Commercial Asset SEATTLE, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has agreed to sell its three marketed hyperimmune products, WinRho® SDF, HepaGam B®, and VARIZIG®, to Saol Therapeuti...

Read More

08/31/17

Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414

Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414 Preliminary Phase I Data Show Markedly Lower Anti-Drug Antibody Titers Demonstrating Effectiveness of New Dosing Regimen SEATTLE, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced the end of its partnership with MorphoSys AG for the joint worldwide development...

Read More

08/17/17

Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications SEATTLE and LUND, Sweden, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience (Nasdaq Stockholm:ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the companies have initiat...

Read More

08/10/17

Aptevo Therapeutics Reports Second Quarter 2017 Financial Results

Showcases Differentiating Features of the ADAPTIR™ Protein Therapeutic Platform at Prominent Industry Conferences Signs Collaboration Agreement with Alligator Bioscience Expanding Aptevo’s Portfolio to Include a New Bispecific Antibody Candidate with a Novel Mechanism of Action Targeting 4-1BB, a Compelling Biological Pathway Implicated in Numerous Solid Tumor Indications SEATTLE, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on ...

Read More

07/20/17

Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy

Strategic Partnership Will Advance Development of a Novel Bispecific Immuno-Oncology Antibody Targeting Compelling Biological Pathway Implicated in Multiple Solid Tumor Indications Focuses on New Mechanism of Action of Tumor Targeting Demonstrating the Versatility of Alligator’s Antibody Discovery Platform ALLIGATOR-GOLD® and Aptevo’s ADAPTIR™ Protein Therapeutic Platform SEATTLE and LUND, Sweden, July 20, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnolog...

Read More

06/07/17

Aptevo Therapeutics Highlights Key Features of Its ADAPTIR™ Protein Therapeutic Platform at Two Industry Conferences

SEATTLE, June 07, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that aspects of its ADAPTIR™ protein therapeutic platform were showcased recently at the Americas Antibody Congress 2017 in San Diego, May 23-24, 2017, and at the 2017 Next Generation Protein Therapeutics Summit in San Diego, June 5-7, 2017. In a presentation entitled, “From the Bench to the Clinic...

Read More

05/12/17

Aptevo Therapeutics Reports First Quarter 2017 Financial Results

Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the 2016 PEPTALK Conference Showcasing Advantages of the ADAPTIR™ Platform SEATTLE, May 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2017. “Aptevo made important strides in early 2017 in both...

Read More

05/05/17

Aptevo Therapeutics Presents Detailed Overview of its Adaptir™ Protein Therapeutic Platform at the 13th Annual Pegs Summit

Key Advantages of the ADAPTIR Platform Showcased During the  ‘Bispecific Antibodies in Oncology’ Session SEATTLE, May 05, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that it presented information on the Company’s ADAPTIR™ protein therapeutic platform at the 13th Annual Protein Engineering (PEGS Summit) in Boston, May 1-4, 2017.  Dr. Peter Pavlik, Principal Sc...

Read More

04/10/17

Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B

Data Presented at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium SEATTLE, April 10, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new clinical data evaluating the safety and efficacy of IXINITY® [Coagulation Factor IX (Recombinant)] in previously treated patients under 12 years of age with Hemophilia B.  The data suggest t...

Read More

04/03/17

Aptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation

New Preclinical Data Presented at the 2017 American Association for Cancer Research Annual Meeting Demonstrate Antibody-like Characteristics and Efficacy of Redirected T-Cell Cytotoxicity Therapeutic Approach Antibody-like Serum Half-life in Mice of up to 12.5 days – Significantly Longer than Other Bispecific Antibody Candidates in Development   SEATTLE, April 03, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and...

Read More

03/31/17

Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update

Advances Multiple Clinical and Preclinical Candidates Based on the Company’s  Novel ADAPTIR™ Protein Therapeutic Platform Achieves 30% Increase in Year-Over-Year Product Sales Revenue SEATTLE, March 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today reported its financial results for the year ended December 31, 2016 and provided an update on its commercial portfolio and pipeline...

Read More

03/15/17

Aptevo Therapeutics Announces New IXINITY Supply Available May 2017

Initial Bulk Drug Substance Batch Successfully Manufactured SEATTLE, March 15, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the successful manufacture of a recent bulk drug substance (BDS) batch of IXINITY® [Coagulation Factor IX (Recombinant)].  Consequently, Aptevo anticipates that new supply will be available beginning in May 2017, after the completion of routine fi...

Read More

03/14/17

Aptevo Therapeutics Expands Bispecific Antibody Portfolio

Preclinical Data on New Anti-CD123 ADAPTIR™ Bispecific Candidates to be Presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting SEATTLE, March 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting ...

Read More

03/06/17

Aptevo Therapeutics to Present at the 29th Annual ROTH Conference

SEATTLE, March 06, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 10:30 AM PT at the Ritz Carlton, Laguna Niguel, California. A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Eve...

Read More

01/13/17

Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions

SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has received a $20 million cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent, effective August 1, 2016. With the additional $20 million cash payment announced today, Emergent has provided a total of $65 million in cash...

Read More

01/12/17

Aptevo Therapeutics Presents Data on Its ADAPTIR™ Antibody Platform at the 16th Annual PEPTALK Conference

Preclinical Data Presented Show that ADAPTIR™ Platform Offers Unique Approach for Generating Bispecific Antibodies with Favorable Therapeutic Profile SEATTLE, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that Dr. John Blankenship, a Lead Scientist at Aptevo, presented new data on the Company’s bispecific antibody program based on the ADAPTIR platform technolog...

Read More

01/04/17

Aptevo Therapeutics Resumes IXINITY Manufacturing; Anticipates Re-Entering the Market in the Second Quarter of 2017

SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has resumed IXINITY® manufacturing operations and anticipates that new supply of IXINITY will be available beginning in the second quarter of 2017. Today’s announcement follows a Notice of Interruption in Manufacturing submitted by Aptevo to the Food and Drug Administration (FDA) and reported in t...

Read More

12/16/16

Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab

Data Show Improved Overall Response Rate and Progression Free Survival with Combination Otlertuzumab/Bendamustine Therapy SEATTLE, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the publication of positive data from a Phase 2 clinical trial evaluating its proprietary humanized monospecific anti-CD37 protein therapeutic, otlertuzumab. The results were recently pub...

Read More

12/15/16

Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414

SEATTLE, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has amended the terms of its collaboration agreement with MorphoSys AG, originally executed in August 2014, for the joint worldwide development and commercialization of MOR209/ES414, a novel bispecific immuno-oncology therapeutic currently being evaluated in a Phase 1 clinical study for the treatment ...

Read More

11/23/16

Aptevo Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

SEATTLE, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 1:00 pm EST at the Lotte New York Palace Hotel. A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events....

Read More

09/15/16

Aptevo Therapeutics Augments Leadership Team

Appoints Former GlaxoSmithKline Executive Randy Maddux  Senior Vice President, Operations Jane Gross, Ph.D., Promoted to Senior Vice President and Chief Scientific Officer SEATTLE, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that Randy J. Maddux has joined the Company as Senior Vice President, Operations, effective July 2016.  Mr. Maddux brings more than 3...

Read More

08/05/16

Aptevo Therapeutics Closes $35 Million Term Loan Agreement

SEATTLE--(BUSINESS WIRE)--Aug. 5, 2016-- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has closed on a $35 million term loan agreement previously announced on August 1, 2016. “The $35 million term loan agreement further strengthens our balance sheet and provides additional operational flexibility at an attractive cost of capital,” st...

Read More

08/01/16

Aptevo Therapeutics Secures $35 Million Term Loan Agreement

SEATTLE--(BUSINESS WIRE)--Aug. 1, 2016-- Aptevo Therapeutics Inc. (“Aptevo”; “the Company”) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has reached agreement with MidCap Financial on the final terms on a $35 million term loan. The agreement provides Aptevo with up to $35 million of available borrowing capacity, which will be available to the Company in two tranches of $1...

Read More

08/01/16

Aptevo Therapeutics Completes Separation from Emergent BioSolutions

SEATTLE--(BUSINESS WIRE)--Aug. 1, 2016-- Aptevo Therapeutics Inc. (“Aptevo”) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) and its launch as an independent, publicly traded corporation. Aptevo common stock will begin "regular way" trading under the symbol “APVO” on the Nasdaq Global Se...

Read More

07/20/16

Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock

GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc. (NYSE:EBS) of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, Emergent announced that Aptevo common stock will commence trading today, July 20, 2016, on a "when issued" basis under the symbol "APVOV" on the Nasdaq Global S...

Read More

07/15/16

Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement

Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Registration Statement on Form 10 filed by Aptevo Therapeutics Inc. has been declared effective by the U.S. Securities and Exchange Commission. The Registration Statement on Form 10, available at www.emergentbiosolutions.com/spinoff, includes material information regarding Aptevo's business an...

Read More

07/11/16

Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio

GAITHERSBURG, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. Emergent expects to complete the distribution of Aptevo common stock to Emergent ...

Read More

04/15/16

Emergent BioSolutions Announces Filing of Form 10 Registration Statement for Its Planned Spin-Off of Its Biosciences Business Aptevo Therapeutics

GAITHERSBURG, Md., April 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission in connection with the company's previously announced plan to spin-off certain assets of its biosciences business to create a separate, publicly-traded company, Aptevo Therapeutics Inc. The transaction is intended to qualify as a tax-free spin-off to the company's stockholders and is t...

Read More